La diabetes mellitus y las complicaciones cardiovasculares

Olga Lidia Pereira Despaigne, Maricela Silvia Palay Despaigne, Argenis Rodríguez CascaretIII, Rafael Manuel Neyra Barros

Texto completo:

PDF HTML

Resumen

Las enfermedades cardiovasculares en las personas con diabetes mellitus son más precoces y malignas, y suelen presentarse con síntomas y signos atípicos.  Igualmente, se ha demostrado que la hiperglucemia es un importante factor de riesgo para las complicaciones microangiopáticas y macroangiopáticas en la diabetes mellitus, y la hiperglucemia posprandial, con glucemia en ayunas normal, es una condición clínica frecuente y un factor de riesgo cardiovascular independiente.  Así, en el presente trabajo se exponen algunas consideraciones relacionadas con el control de las dislipidemias, la hipertensión arterial y la antiagregación plaquetaria en el paciente con diabetes mellitus.

 

Palabras clave

complicaciones cardiovasculares, hiperglucemia, dislipidemias, hipertensión arterial, antiagregación plaquetaria.

Referencias

Anderson KM, Wilson PW, Odell PM, Kannel WB. An update coronary risk profile. A statement for health professionals. Circulation. 1991; 83(1): 356-62.

Conroy RM, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003; 24: 987-1003.

De Backer G, Ambrosioni E, Borch Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J. 2003; 24(17): 1601-10.

Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III, or ATP III). JAMA. 2001; 285(19): 2486-97.

Grundy SM. Primary prevention of coronary heart disease: integrating risk assessment with intervention. Circulation. 1999; 100(9): 988-98.

Orozco D, Fernandez I, Carratala C. Diabetes y cumplimiento terapéutico. Medicina Clínica. 2001; 116(supl. 2): 20-4.

Vijan S, Hayward RA; American College of Physicians. Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians. Ann Intern Med. 2004; 140(8): 650-8.

Orozco Beltrán D, Gil Guillen VF, Quirce F, Navarro Perez J, Pineda M, Gomez de la Camara A, et al. Control of diabetes and cardiovascular risk factors in patients with type 2 diabetes in primary care. The gap between guidelines and reality in Spain. Int J Clin Pract. 2007; 61(6): 909-15.

Brotons C, Royo Bordonada MA, Álvarez Sala L, Armario P, Artigao R, Conthe P, et al. Adaptación española de la Guía Europea de Prevención Vascular. Rev Esp Salud Publica. 2004; 78(4): 435-8.

American Diabetes Association. Standards of medical care in diabetes--2006. Diabetes Care. 2006; 29(Supl 1): 4-42.

García Navarro D, Orozco Beltrán D, Gil Guillén V, Carratalá Munuera C, Terol Moltó C, Merino Sánchez J. Relación entre cumplimiento farmacológico y grado de control en pacientes con hipertensión, diabetes o dislipemias. Med Clin (Barc). 2001; 116(Supl.) 2:26-30.

Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for the prevention of death, myocardial infarction and stroke in high risk patients. BMJ. 2002; 324(7329):71-86.

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ. 1994; 308(6921):81-106.

Colwell JA; American Diabetes Association. Aspirin therapy in diabetes. Diabetes Care. 2004; 27(Suppl 1): 72-3.

American Diabetes Association. Standards of Medical Care in Diabetes--2008. Diabetes Care. 2008; 31(Supl.1): 512-54.

ETDRS investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study Report 14. JAMA. 1992; 268(10): 1292-300.

Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998; 351(9118): 1755-62.

Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A, et al. Primary prevention of cardiovascular events with low dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care. 2003; 26(12): 3264-72.

CAPRIE Steering Committee. A randomised blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996; 348(9038): 1329-39.

The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Eng J Med. 2001; 345: 494-502.

Donnelly R, Emslie-Smith AM, Gardner ID, Morris AD. Vascular complications of diabetes. BMJ. 2000; 320: 1062-6.

Vinocour MV, Tortós JE. Diabetes mellitus, una enfermedad cardiovascular. Rev Costarr Cardiol. 2007; 4(1): 36-44.

lnzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA. 2002; 287(3): 360-72.

Holmboe ES. Oral antihyperglycemic therapy for type 2 diabetes: clinical applications. JAMA. 2002; 287(3): 373-6.

Ragucci E, Zonszein J, Frishman WH. Pharmacotherapy of diabetes mellitus: implications for the prevention and treatment of cardiovascular disease. Heart Dis. 2003; 5(1): 18-33.



Bookmark and Share


Licencia de Creative Commons
Esta obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial 4.0 Internacional.